Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 1/20 | 0.47 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468918 | 0.89 | MAPK14 (0.52) | — | |
| SCHEMBL4835253 | 0.89 | TRPC3 (0.49) | TRPC3TRPC7 | |
| SCHEMBL4893233 | 0.88 | TRPC3 (0.47) | TRPC3TRPC7 | |
| SCHEMBL4906701 | 0.88 | TRPC3 (0.47) | TRPC3TRPC7 | |
| SCHEMBL4470242 | 0.82 | TRPC3 (0.51) | TRPC3TRPC7GRIN2B | |
| SCHEMBL4835277 | 0.80 | — | — | |
| SCHEMBL4838636 | 0.77 | TRPC3 (0.46) | TRPC3TRPC7GRIN2B | |
| SCHEMBL4832799 | 0.77 | USP7 (0.48) | — | |
| SCHEMBL4458503 | 0.77 | TRPC3 (0.53) | TRPC3TRPC7GRIN2B | |
| SCHEMBL14064418 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429590-B2 | Antiprotozoal imidazopyridine compounds | MERCK & CO. INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060293303-A1 | Antiprotozoal imidazopyridine compounds | MERCK SHARP & DOHME LLC | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293303-A1 | Antiprotozoal imidazopyridine compounds | PNPO, PIR, PNP | TRPC3 4659/4885TRPC7 4549/4885CYP3A4 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.